RxDoctor Payments DataLook up a doctor →

Deborah Copeland, MD

Family Medicine · Hattiesburg, MSNPI 1316058787

Payments from drug & device makers

$12,998in general payments, 2019–2025

Across 878 payments — averaging $14.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • AbbVie$1K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$746
  • GSK$695
  • plus $5K from 31 others

What the payments were for

  • Food & beverage$12,998100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,998 in reported general payments places this provider in the 95th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$222,121
Medicare patients
609
Services billed
8,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide76$80,320
OzempicSemaglutide46$47,771
JardianceEmpagliflozin40$41,585
FarxigaDapagliflozin Propanediol46$38,566
RybelsusSemaglutide24$24,278
JanuviaSitagliptin Phosphate29$22,236
EliquisApixaban24$16,812
LinzessLinaclotide22$16,736
TrulicityDulaglutide14$15,564
Tresiba Flextouch U-200Insulin Degludec15$11,817
TradjentaLinagliptin14$11,123
Janumet XrSitagliptin Phos/Metformin Hcl13$7,831
Novolog FlexpenInsulin Aspart23$3,881
Rosuvastatin Calcium215$3,473
PaxlovidNirmatrelvir/Ritonavir29$2,859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$746$95,88390 claims
Novo NordiskOzempic, Rybelsus$2,282$72,04970 claims
Boehringer IngelheimJardiance, Tradjenta$1,065$52,70854 claims
AstraZenecaFarxiga$1,478$38,56646 claims
MerckJanuvia, Janumet Xr$262$30,06642 claims
PfizerEliquis, Paxlovid$300$19,67153 claims
AbbVieLinzess, Synthroid$1,423$18,36247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →